KR20040107525A - 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도 - Google Patents

치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도 Download PDF

Info

Publication number
KR20040107525A
KR20040107525A KR10-2004-7018340A KR20047018340A KR20040107525A KR 20040107525 A KR20040107525 A KR 20040107525A KR 20047018340 A KR20047018340 A KR 20047018340A KR 20040107525 A KR20040107525 A KR 20040107525A
Authority
KR
South Korea
Prior art keywords
chloro
dihydroquinoline
oxo
carboxylic acid
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7018340A
Other languages
English (en)
Korean (ko)
Inventor
티모씨 비.씨. 존스톤
더크 제이. 호젠캠프
켈빈 더블유. 지
Original Assignee
더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전트 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전트 오브 더 유니버시티 오브 캘리포니아
Publication of KR20040107525A publication Critical patent/KR20040107525A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR10-2004-7018340A 2002-05-14 2003-05-12 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도 Ceased KR20040107525A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
US60/380,641 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (1)

Publication Number Publication Date
KR20040107525A true KR20040107525A (ko) 2004-12-20

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7018340A Ceased KR20040107525A (ko) 2002-05-14 2003-05-12 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도

Country Status (16)

Country Link
US (2) US7355047B2 (https=)
EP (1) EP1503759B1 (https=)
JP (1) JP4532263B2 (https=)
KR (1) KR20040107525A (https=)
CN (1) CN1652784A (https=)
AT (1) ATE417613T1 (https=)
AU (1) AU2003229043B2 (https=)
BR (1) BR0309965A (https=)
CA (1) CA2484308A1 (https=)
DE (1) DE60325347D1 (https=)
DK (1) DK1503759T3 (https=)
ES (1) ES2319176T3 (https=)
IL (1) IL164734A0 (https=)
MX (1) MXPA04011156A (https=)
NZ (1) NZ536061A (https=)
WO (1) WO2003097564A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1503759T3 (da) * 2002-05-14 2009-04-14 Univ California Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
RU2006142896A (ru) * 2004-05-06 2008-06-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Замещенные енаминоны, их производные и их применение
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101155787B (zh) * 2005-04-11 2010-11-24 弗·哈夫曼-拉罗切有限公司 (3,4-二氢-喹唑啉-2-基)-茚满-1-基-胺
DE602006010540D1 (de) * 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2645376C (en) * 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
CA2660421A1 (en) * 2006-08-10 2008-02-14 Ferrer Internacional S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
NZ576036A (en) 2006-10-16 2010-10-29 Bionomics Ltd Naphthyridine containing compounds for treating anxiety disorders
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8436016B2 (en) * 2008-10-23 2013-05-07 Scott D. Kuduk Fused heterocyclic M1 receptor positive allosteric modulators
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
WO2010114919A2 (en) * 2009-04-02 2010-10-07 Stc.Unm Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9023848B2 (en) 2011-03-02 2015-05-05 Bionomics Limited Small-molecules as therapeutics
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
EP2707367B1 (en) 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (https=) * 1974-06-11 1982-04-01
US4390541A (en) * 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
DE60018274T2 (de) * 1999-05-06 2005-08-04 Neurogen Corp., Branford Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
DK1503759T3 (da) * 2002-05-14 2009-04-14 Univ California Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf

Also Published As

Publication number Publication date
WO2003097564A3 (en) 2004-02-26
NZ536061A (en) 2008-09-26
AU2003229043B2 (en) 2008-12-04
US20060178516A1 (en) 2006-08-10
AU2003229043A1 (en) 2003-12-02
EP1503759B1 (en) 2008-12-17
HK1072905A1 (en) 2005-09-16
US7355047B2 (en) 2008-04-08
DK1503759T3 (da) 2009-04-14
EP1503759A2 (en) 2005-02-09
US20080176897A1 (en) 2008-07-24
IL164734A0 (en) 2005-12-18
MXPA04011156A (es) 2005-02-17
EP1503759A4 (en) 2006-02-15
BR0309965A (pt) 2005-03-01
WO2003097564A2 (en) 2003-11-27
JP2005535592A (ja) 2005-11-24
ATE417613T1 (de) 2009-01-15
CA2484308A1 (en) 2003-11-27
ES2319176T3 (es) 2009-05-05
CN1652784A (zh) 2005-08-10
JP4532263B2 (ja) 2010-08-25
DE60325347D1 (de) 2009-01-29

Similar Documents

Publication Publication Date Title
KR20040107525A (ko) 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도
RU2309149C2 (ru) Способ получения 7-замещенного-3-хинолин и 3-хинол-4-он карбонитрилов
HU229549B1 (en) Substituted 3-cyano quinolines, process for producing them and use of them and pharmaceutical compositions containing them
US7214690B2 (en) Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
KR101278383B1 (ko) 퀴놀론 화합물 및 제약 조성물
US6656941B2 (en) Aryl substituted tetrahydroindazoles
JP2008501763A (ja) バニロイドアンタゴニストとして有用なキナゾリノン誘導体
RU2595894C2 (ru) Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
US5916898A (en) Phenanthroline derivatives
US6660736B2 (en) Phthalimido derivatives and a process for their preparation
KR20080070749A (ko) 개폐 이온 통로를 조절하기 위한 조성물 및 방법
RU2581362C2 (ru) Замещенные 2-оксо- и 2- тиоксо- дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
Sato et al. Discovery of benzo [f] pyrido [4, 3-b][1, 4] oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model
US6861529B2 (en) Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
CN111205244B (zh) 噻唑并环类化合物、其制备方法、中间体和应用
US6743817B2 (en) Substituted fused pyrroleimines and pyrazoleimines
US7176213B2 (en) Imidazoquinoline derivatives and their use as adenosine A3 ligands
TWI564300B (zh) 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑
HK1072905B (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
JP2005516901A (ja) １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物
CN110256416B (zh) 组蛋白去乙酰化酶抑制剂及其制备方法与用途
US6673811B1 (en) 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
TWI402264B (zh) 芳基甲基苯并喹唑啉酮ｍ１受體之正向異位性調節劑
Fluoroquinolones Research Journal of Pharmaceutical, Biological and Chemical Sciences
US20080032975A1 (en) Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080509

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100723

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101206

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100723

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I